Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accounts Payables (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Accounts Payables for 16 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 7.55% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 7.55% year-over-year, with the annual reading at $6.0 million for FY2025, 7.55% up from the prior year.
  • Accounts Payables for Q4 2025 was $6.0 million at Anika Therapeutics, up from $4.7 million in the prior quarter.
  • The five-year high for Accounts Payables was $10.0 million in Q1 2024, with the low at $4.7 million in Q3 2025.
  • Average Accounts Payables over 5 years is $7.5 million, with a median of $7.9 million recorded in 2021.
  • The sharpest move saw Accounts Payables skyrocketed 31.47% in 2021, then crashed 52.26% in 2025.
  • Over 5 years, Accounts Payables stood at $7.6 million in 2021, then increased by 18.88% to $9.1 million in 2022, then tumbled by 31.74% to $6.2 million in 2023, then fell by 9.32% to $5.6 million in 2024, then increased by 7.55% to $6.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $6.0 million, $4.7 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.